Celularity and DefEYE, Inc. Partner to Advance Growth of Regenerative Therapies in Eye Care
Celularity (Nasdaq: CELU) announced a strategic partnership with DefEYE, including an exclusive sublicense and pricing arrangement tied to Celularity’s in-kind investment in DefEYE’s $12MM Series Seed Preferred Equity round.
DefEYE, formed from Verséa Ophthalmics leadership, reported ~70% sales growth in 2024 and plans to use funding to launch decellularized ophthalmic biologics including Biovance, Biovance 3L, Interfyl and related R&D. Celularity will be DefEYE’s exclusive contract manufacturer for the ophthalmic portfolio and retains the right to name one of five board members.
Celularity (Nasdaq: CELU) ha annunciato una partnership strategica con DefEYE, inclusa una sublicenza esclusiva e un accordo di pricing legato all'investimento in-kind di Celularity nel round $12MM Series Seed Preferred Equity di DefEYE.
DefEYE, nata dallo staff dirigente di Verséa Ophthalmics, ha riportato ~un 70% di crescita delle vendite nel 2024 e prevede di utilizzare i fondi per lanciare biologici oftalmici decellularizzati tra cui Biovance, Biovance 3L, Interfyl e relative attività di R&D. Celularity sarà l'unico produttore contrattuale per il portafoglio oculare e mantiene il diritto di nominare una delle cinque persone del consiglio.
Celularity (Nasdaq: CELU) anunció una asociación estratégica con DefEYE, que incluye una sublicencia exclusiva y un acuerdo de precios ligado a la inversión in-kind de Celularity en la ronda de $12MM Series Seed Preferred Equity de DefEYE.
DefEYE, formada por el liderazgo de Verséa Ophthalmics, reportó ~un crecimiento de ventas del 70% en 2024 y planea usar los fondos para lanzar biologicos oftálmicos decellularizados, incluyendo Biovance, Biovance 3L, Interfyl y investigaciones y desarrollos relacionados. Celularity será el fabricante contratado exclusivo para el portafolio oftálmico y conserva el derecho a nombrar a una de las cinco personas del consejo.
Celularity (나스닥: CELU)는 DefEYE와의 전략적 파트너십을 발표했으며, DefEYE의 $12MM 시리즈 시드 우선주 라운드에 대한 Celularity의 현물 투자에 연계된 독점 하청권과 가격 책정 합의를 포함합니다.
DefEYE는 Verséa Ophthalmics의 리더십에서 형성되었으며, 2024년 매출 성장률 약 70%를 보고했고 자금을 활용해 생체조직 decellularized 안과 바이오의약품를 포함한 Biovance, Biovance 3L, Interfyl 및 관련 연구개발을 출시할 계획입니다. Celularity는 안과 포트폴리오의 독점 계약 제조사가 되며 이사회 다섯 명 중 한 명을 지명할 권리를 보유합니다.
Celularity (NASDAQ : CELU) a annoncé un partenariat stratégique avec DefEYE, incluant une sous-licence exclusive et un accord de tarification lié à l'investissement in-kind de Celularity dans la ronde $12MM Series Seed Preferred Equity de DefEYE.
DefEYE, issue du leadership de Verséa Ophthalmics, a enregistré une croissance des ventes d'environ 70 % en 2024 et prévoit d'utiliser les fonds pour lancer des biologiques ophtalmiques décellularisés, dont Biovance, Biovance 3L, Interfyl et les recherches et développements connexes. Celularity sera le fabricant sous contrat exclusif pour le portefeuille ophtalmique et conserve le droit de nommer l'un des cinq membres du conseil.
Celularity (Nasdaq: CELU) kündigte eine strategische Partnerschaft mit DefEYE an, einschließlich einer exklusiven Unterlizenz und einer Preisvereinbarung, die an die in-kind Investition von Celularity in DefEYE's $12MM Series Seed Preferred Equity-Runde gebunden ist.
DefEYE, aus der Führung von Verséa Ophthalmics hervorgegangen, meldete einen ca. 70%-igen Umsatzanstieg im Jahr 2024 und plant, die Mittel zu verwenden, um decellulalisierte ophthalmische Biologika, einschließlich Biovance, Biovance 3L, Interfyl, sowie damit verbundene F&E auf den Markt zu bringen. Celularity wird für das ophthalmische Portfolio der exklusive Vertragshersteller sein und behält das Recht, eines von fünf Vorstandsmitgliedern zu benennen.
Celularity (ناسداك: CELU) أعلنت عن شراكة استراتيجية مع DefEYE، بما في ذلك ترخيص فرعي حصري واتفاق تسعير مرتبط باستثمار Celularity في DefEYE العيني ضمن جولة $12MM Series Seed Preferred Equity.
DefEYE، المكوَّن من قيادة Verséa Ophthalmics، أبلغ عن نمو مبيعات يقارب ~70% في عام 2024 ويخطط لاستخدام التمويل لإطلاق بيولوجيات عينية مخلّصة الخلايا بما في ذلك Biovance، Biovance 3L، Interfyl وغيرها من البحث والتطوير ذات الصلة. ستصبح Celularity المصنِّع التعاقدي الحصري لمحفظة العين وتحتفظ بحق تسمية أحد أعضاء مجلس الإدارة الخمسة.
- $12MM Series Seed Preferred Equity funding for DefEYE
- DefEYE ~70% sales growth in 2024
- Celularity granted an exclusive sublicense for ophthalmic biologics
- Celularity designated as exclusive contract manufacturer
- Celularity retains the right to name 1 of 5 DefEYE board members
- None.
Insights
Exclusive license and manufacturing deal plus a
Celularity provided an in-kind investment tied to an exclusive sublicense and pricing arrangement covering its ophthalmic biologics portfolio, including Biovance®, Biovance® 3L, Interfyl®, and CentaFlex. DefEYE will use the
Key dependencies include DefEYE’s ability to scale sales and regulatory compliance for ophthalmic use, plus execution of the exclusive pricing terms by both parties. Reported sales momentum in 2024 rose by
Watch for three monitorable items: confirmation of initial commercial shipments and manufacturing timelines, the impact of the exclusive pricing on product margins, and any regulatory clearances or filings for ophthalmic indications. Expect updates on these items within the next 12–24 months and on routine funding or milestone disclosures tied to scaling activities.
FLORHAM PARK, N.J., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a regenerative and cellular medicine company addressing age-related and degenerative diseases, announced today a strategic partnership with DefEYE, Inc. (“DefEYE”), a newly established ophthalmic product and technology company. Celularity has executed an exclusive license & pricing arrangement with DefEYE on the backend of Celularity’s in-kind investment in DefEYE’s
DefEYE was established to build on Verséa Ophthalmics’ commercial momentum, reflected in significant year-over-year sales growth since its August 2022 launch. According to DefEYE, sales increased in 2024 by nearly
- Single and tri-layer Decellularized Amniotic Basement Membrane, Biovance® and Biovance® 3L Ocular, respectively.
- Interfyl®, a flowable human connective tissue derived from the chorionic plate.
- Collaborative research and development for future commercial products.
Celularity granted DefEYE an exclusive sublicense to Celularity’s ophthalmic biologics portfolio, which includes Biovance®, Biovance® 3L, Interfyl®, and CentaFlex. Celularity will be the exclusive contract manufacturer for DefEYE’s portfolio of ophthalmic biologics solutions.
“The partnership reflects a strategic opportunity to align for both companies and signals the start of a promising new chapter for regenerative therapies in eye care,” said Robert J. Hariri, M.D., Ph.D., Celularity’s Chairman and CEO. “Our in-kind investment and exclusive license and pricing agreement exemplify Celularity’s commitment to drive innovation through strategic partnerships. We are excited to be part of DefEYE’s focused expansion into the ophthalmic space and to demonstrate the transformative power of placental-derived regenerative biologic solutions. This strategy fits into our objective of accessing new markets for our portfolio of commercial products,” Hariri said.
DefEYE’s leadership includes key personnel from the original Verséa Ophthalmics team, ensuring continuity of expertise and relationships in the rapidly evolving eye care market. Celularity has the right to name one member of DefEYE’s five-member board of directors.
“This strategic collaboration with Celularity strengthens our capabilities and core competencies,” said Rob Sambursky, M.D., CEO of DefEYE, Inc. “With Celularity’s deep scientific and manufacturing expertise, we believe that we will be well positioned to scale and deliver meaningful clinical management solutions to both physicians and patients.”
About Celularity Inc.
Celularity Inc. (Nasdaq: CELU) is a regenerative and aging-related cellular medicine company developing, manufacturing, and commercializing advanced biomaterial products and allogeneic and autologous cell therapies, all derived from the postpartum placenta. Celularity believes that by harnessing the placenta’s unique biology and ready availability, it can develop therapeutic solutions that address significant unmet global needs for effective, accessible, and affordable therapies that target fundamental aging mechanisms like cellular senescence, age-related chronic inflammation, and tissue degeneration. For more information about Celularity and its cutting-edge regenerative medicine solutions, please visit www.celularity.com
About DefEYE, Inc.
DefEYE, Inc. is a rapidly growing ocular company on a mission to transform and personalize therapeutic approaches in eye care. The company focuses on delivering a portfolio of innovative decellularized biologic solutions that optimize treatment and management of various eye care conditions, including ocular surface diseases, pterygium surgery, and other surgical interventions.
Forward Looking Statements
Certain statements in this press release are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements regarding: (i) our future sales or sales growth; (ii) our expectations for future financial results, including levels of net sales; (iii) our expectations regarding new products including our 510K products; and (iv) future demand for our products. All statements other than statements of historical facts are “forward-looking statements,” including those relating to future events. In some cases, you can identify forward-looking statements by terminology such as “anticipate,” “believe,” “can,” “could,” “continue,” “expect,” “improving,” “may,” “observed,” “potential,” “promise,” “should,” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances). Forward-looking statements are based on Celularity’s current expectations and assumptions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks, and changes in circumstances that may differ materially from those contemplated by the forward-looking statements, which are neither statements of historical fact nor guarantees or assurances of future performance. Many factors could cause actual results to differ materially from those described in these forward-looking statements, including those risk factors set forth under the caption “Risk Factors” in Celularity’s annual report on Form 10-K and Form 10-K/A for the year ended December 31, 2024 filed with the Securities and Exchange Commission (SEC) on May 8, 2025 and May 21, 2025, respectively, and other filings with the SEC. If any of these risks materialize or underlying assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. There may be additional risks that Celularity does not presently know, or that Celularity currently believes are immaterial, that could also cause actual results to differ from those contained in the forward-looking statements. In addition, these forward-looking statements reflect Celularity’s current expectations, plans, or forecasts of future events and views as of the date of this communication. Subsequent events and developments could cause assessments to change. Accordingly, forward-looking statements should not be relied upon as representing Celularity’s views as of any subsequent date, and Celularity undertakes no obligation to update forward-looking statements contained herein, whether because of any new information, future events, changed circumstances or otherwise, except as otherwise required by law.
Investor and Media Contact:
Carlos Ramirez
Senior Vice President, Celularity Inc.
carlos.ramirez@celularity.com
Media Contact:
Rahim K. Hirji, RPh
Senior Vice President, DefEYE, Inc.
rhirji@defeye.com
FAQ
What did Celularity announce on October 30, 2025 regarding DefEYE (CELU)?
How will the Celularity and DefEYE deal affect CELU’s business operations?
Which ophthalmic products are included in the Celularity-DefEYE partnership (CELU)?
What funding and commercialization milestones did DefEYE report in the partnership announcement?
Does Celularity get board representation from the DefEYE transaction (CELU)?
